Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 57

1.

Rejection of the Renal Allograft in the Absence of Demonstrable Antibody and Complement.

Zhao X, Huang G, Randhawa S, Zeng G, Lunz J, Randhawa P.

Transplantation. 2016 Feb 19. [Epub ahead of print]

PMID:
26901079
2.

Long-term outcomes and predictors in pediatric liver retransplantation.

Dreyzin A, Lunz J, Venkat V, Martin L, Bond GJ, Soltys KA, Sindhi R, Mazariegos GV.

Pediatr Transplant. 2015 Dec;19(8):866-74. doi: 10.1111/petr.12588. Epub 2015 Sep 12.

PMID:
26362966
3.

Breast tumor kinase/protein tyrosine kinase 6 (Brk/PTK6) activity in normal and neoplastic biliary epithelia.

Mizuguchi Y, Specht S, Isse K, Sasatomi E, Lunz JG 3rd, Takizawa T, Demetris AJ.

J Hepatol. 2015 Aug;63(2):399-407. doi: 10.1016/j.jhep.2015.02.047. Epub 2015 Mar 12.

PMID:
25770659
4.

Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions.

Haas M, Sis B, Racusen LC, Solez K, Glotz D, Colvin RB, Castro MC, David DS, David-Neto E, Bagnasco SM, Cendales LC, Cornell LD, Demetris AJ, Drachenberg CB, Farver CF, Farris AB 3rd, Gibson IW, Kraus E, Liapis H, Loupy A, Nickeleit V, Randhawa P, Rodriguez ER, Rush D, Smith RN, Tan CD, Wallace WD, Mengel M; Banff meeting report writing committee.

Am J Transplant. 2014 Feb;14(2):272-83. doi: 10.1111/ajt.12590. Erratum in: Am J Transplant. 2015 Oct;15(10):2784. Rangel, Erika [corrected to Rangel, Erika B].

5.

Small proline rich protein 2a in benign and malignant liver disease.

Mizuguchi Y, Isse K, Specht S, Lunz JG 3rd, Corbitt N, Takizawa T, Demetris AJ.

Hepatology. 2014 Mar;59(3):1130-43. doi: 10.1002/hep.26889. Epub 2014 Jan 27.

PMID:
24123265
6.

Comprehensive assessment and standardization of solid phase multiplex-bead arrays for the detection of antibodies to HLA-drilling down on key sources of variation.

Reed EF, Rao P, Zhang Z, Gebel H, Bray RA, Guleria I, Lunz J, Mohanakumar T, Nickerson P, Tambur AR, Zeevi A, Heeger PS, Gjertson D.

Am J Transplant. 2013 Nov;13(11):3050-1. doi: 10.1111/ajt.12462. Epub 2013 Sep 18. No abstract available.

7.

Minimal effect of bortezomib in reducing anti-pig antibodies in human leukocyte antigen-sensitized patients: a pilot study.

Hara H, Bentall A, Long C, Fang J, Andreyev O, Lunz J, Ezzelarab M, Abu-Elmagd KM, Shapiro R, Ayares D, Stegall M, Cooper DK.

Xenotransplantation. 2013 Nov-Dec;20(6):429-37. doi: 10.1111/xen.12052. Epub 2013 Sep 3.

8.

Cylex ImmuKnow Cell Function Assay.

Zeevi A, Lunz J.

Methods Mol Biol. 2013;1034:343-51. doi: 10.1007/978-1-62703-493-7_21.

PMID:
23775749
9.

Comprehensive assessment and standardization of solid phase multiplex-bead arrays for the detection of antibodies to HLA.

Reed EF, Rao P, Zhang Z, Gebel H, Bray RA, Guleria I, Lunz J, Mohanakumar T, Nickerson P, Tambur AR, Zeevi A, Heeger PS, Gjertson D.

Am J Transplant. 2013 Jul;13(7):1859-70. doi: 10.1111/ajt.12287. Epub 2013 Jun 13.

10.

SPRR2A expression in cholangiocarcinoma increases local tumor invasiveness but prevents metastasis.

Specht S, Isse K, Nozaki I, Lunz JG 3rd, Demetris AJ.

Clin Exp Metastasis. 2013 Oct;30(7):877-90. doi: 10.1007/s10585-013-9589-2. Epub 2013 Jun 1.

PMID:
23728799
11.

The big picture: A case report of antibody mediated rejection and treatment after lung transplantation illustrating the need to correlate laboratory findings with clinical status.

Zeevi A, Marrari M, Lunz J, Lomago J, Johnson K, Jelinek L, Foster D, Bermudez C, McDyer J, Pilewski J, Ensor C.

Clin Transpl. 2013:399-405.

PMID:
25095535
12.

Gut bacteria drive Kupffer cell expansion via MAMP-mediated ICAM-1 induction on sinusoidal endothelium and influence preservation-reperfusion injury after orthotopic liver transplantation.

Corbitt N, Kimura S, Isse K, Specht S, Chedwick L, Rosborough BR, Lunz JG, Murase N, Yokota S, Demetris AJ.

Am J Pathol. 2013 Jan;182(1):180-91. doi: 10.1016/j.ajpath.2012.09.010. Epub 2012 Nov 14.

13.

Preexisting epithelial diversity in normal human livers: a tissue-tethered cytometric analysis in portal/periportal epithelial cells.

Isse K, Lesniak A, Grama K, Maier J, Specht S, Castillo-Rama M, Lunz J, Roysam B, Michalopoulos G, Demetris AJ.

Hepatology. 2013 Apr;57(4):1632-43. doi: 10.1002/hep.26131. Epub 2013 Mar 19.

14.

Persistent strong anti-HLA antibody at high titer is complement binding and associated with increased risk of antibody-mediated rejection in heart transplant recipients.

Zeevi A, Lunz J, Feingold B, Shullo M, Bermudez C, Teuteberg J, Webber S.

J Heart Lung Transplant. 2013 Jan;32(1):98-105. doi: 10.1016/j.healun.2012.09.021. Epub 2012 Nov 9.

15.

Upper-extremity transplantation using a cell-based protocol to minimize immunosuppression.

Schneeberger S, Gorantla VS, Brandacher G, Zeevi A, Demetris AJ, Lunz JG, Metes DM, Donnenberg AD, Shores JT, Dimartini AF, Kiss JE, Imbriglia JE, Azari K, Goitz RJ, Manders EK, Nguyen VT, Cooney DS, Wachtman GS, Keith JD, Fletcher DR, Macedo C, Planinsic R, Losee JE, Shapiro R, Starzl TE, Lee WP.

Ann Surg. 2013 Feb;257(2):345-51. doi: 10.1097/SLA.0b013e31826d90bb.

16.

Preformed and de novo donor specific antibodies in visceral transplantation: long-term outcome with special reference to the liver.

Abu-Elmagd KM, Wu G, Costa G, Lunz J, Martin L, Koritsky DA, Murase N, Irish W, Zeevi A.

Am J Transplant. 2012 Nov;12(11):3047-60. doi: 10.1111/j.1600-6143.2012.04237.x. Epub 2012 Sep 4.

17.

Long-term survival, nutritional autonomy, and quality of life after intestinal and multivisceral transplantation.

Abu-Elmagd KM, Kosmach-Park B, Costa G, Zenati M, Martin L, Koritsky DA, Emerling M, Murase N, Bond GJ, Soltys K, Sogawa H, Lunz J, Al Samman M, Shaefer N, Sindhi R, Mazariegos GV.

Ann Surg. 2012 Sep;256(3):494-508. doi: 10.1097/SLA.0b013e318265f310.

PMID:
22868368
18.

HLA antibody profiling in thoracic transplantation undergoing desensitization therapy.

Zeevi A, Lunz J.

Curr Opin Organ Transplant. 2012 Aug;17(4):416-22. doi: 10.1097/MOT.0b013e328355f1ab. Review.

PMID:
22790076
19.

SPRR2A enhances p53 deacetylation through HDAC1 and down regulates p21 promoter activity.

Mizuguchi Y, Specht S, Lunz JG 3rd, Isse K, Corbitt N, Takizawa T, Demetris AJ.

BMC Mol Biol. 2012 Jun 25;13:20. doi: 10.1186/1471-2199-13-20.

20.

Importance of liver biopsy findings in immunosuppression management: biopsy monitoring and working criteria for patients with operational tolerance.

Banff Working Group on Liver Allograft Pathology.

Liver Transpl. 2012 Oct;18(10):1154-70. doi: 10.1002/lt.23481. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk